Capricor plans new HOPE-3 data and analyses to support a narrower Duchenne approval after an FDA adcomm rejected deramiocel.
After a negative FDA advisory committee vote, Capricor Therapeutics said it will file additional data and analyses on its Duchenne muscular dystrophy therapy in hopes …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
FDA and Capricor spar over HOPE-3 data at an adcomm for a Duchenne cell therapy, as The Lancet publishes results and families…
FDA staff say Capricor's deramiocel fails to show clear efficacy for Duchenne, tanking shares 65%+ ahead of this week's adcomm…
Ahead of a hearing, the FDA raised questions about the benefits of a Duchenne treatment from Capricor Therapeutics, another twist…
Capricor Therapeutics shares surged significantly after the FDA agreed to review new drug data. The company had faced setbacks…
At a contentious meeting with possible implications for other rare disease drugmakers, outside experts ultimately determined that…
Capricor stock plunged after an FDA panel questioned Deramiocel's effectiveness in DMD despite published Phase 3 HOPE-3 trial…
